Dr. Thomas Discusses the Potential Utility for PF-03446962 in HCC

Video

Melanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the potential utility for the monoclonal antibody PF-03446962 in hepatocellular carcinoma (HCC).

Melanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the potential utility for the monoclonal antibody PF-03446962 in hepatocellular carcinoma (HCC).

Treating HCC is challenging because most patients have underlying liver disease, which causes tolerability issues, Thomas says.

PF-03446962, a fully human IgG2 monoclonal antibody against ALK-1, was given to patients intravenously over several weeks. Thomas says the agent was extremely well tolerated with only some minor rash being observed.

A trial is being designed to examine this agent compared with placebo/best supportive care in the second-line setting. Thomas says the randomization will be 2:1, so patients will be twice as likely to get the study drug.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD